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Abstract:
Introduction:
This study evaluated the prevalence and progression of subclinical carotid artery atherosclerosis in active rheumatoid arthritis (RA).
Methods:
Carotid arteries of RA patients were scanned using 3D ultrasound at baseline and 24 weeks for total plaque area, vessel wall volume,
and  intima-media  thickness  (IMT),  as  well  as  arterial  stiffness  measured  using  pulse  wave  velocity.  Variables  related  to
inflammation, lipids and cardiovascular (CV) risk were assessed for associations with plaque progression. Of 195 screened patients,
31 met inclusion criteria (66 Swollen joint count (SJC) plus 68 Tender joint count (TJC)≥8 OR SJC plus TJC≥4 with elevated acute
phase  reactants)  and  were  enrolled  (27  female;  mean  age  59.3±9.8years).  Patients  using  lipid  lowering  drugs  and  uncontrolled
comorbidities were excluded.
Results:
Atherosclerotic  plaque  occurred  in  35%  and  arterial  wall  hypertrophy  (IMT≥0.6mm)  in  86%  of  patients.  Most  (68%)  had  an
abnormal lipid profile characterized by reduced HDL and/or increased total cholesterol/HDL index, which was adversely affected by
disease activity. Stepwise binary logistic regression analysis showed that Framingham risk score (OR=1.155, 95%CI:1.002-1.332,
p=0.046)  and  ESR  (OR=1.148,  95%CI:1.015-1.299,  p=0.028)  predicted  plaque  burden  most  strongly.  Plaque  progression  was
significantly  associated  with  baseline  higher  hsCRP,  ESR,  and  heavy  smoking,  but  only  hsCRP  predicted  plaque  growth  in
multivariate regression analysis (p=0.004); and hsCRP was related to higher disease activity (r=0.443, p=0.016), LDL (r=0.544,
p=0.007), and smoking (r=0.384, p=0.04).
Conclusion:
RA-related inflammation contributed to augmented CV burden in RA and might mediate its effect on atherosclerosis through hsCRP
and modulation of the traditional CV risk factors, such as dyslipidemia.
Keywords: Atherosclerosis, Cardiovascular disease, Carotid plaque progression, Rheumatoid arthritis.
Keymessages:
Active rheumatoid arthritis (RA) with long disease duration had a high prevalence of an abnormal lipid blood1.
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profile, atherosclerotic plaque and carotid artery wall thickness.
Both traditional CV risk factors and inflammatory disease activity were associated with atherosclerotic burden at2.
baseline and their effects might be interrelated: disease activity had a negative impact on lipid blood profile.
High-sensitivity CRP serum level was the only significant risk marker for growing atherosclerotic plaque, as3.
measured by 3D ultrasound for total plaque area over 6 months, after adjustment for other covariates.
The combined effect of traditional cardiovascular risk factors in RA assessed by Framingham risk score failed to4.
predict the high atherosclerotic burden in a quarter of patients; 1.5 multiplication factor recommended for RA
patients did not improve risk estimation.
INTRODUCTION
Cardiovascular (CV) death is the leading cause of mortality in patients with RA. It is responsible for approximately
half the deaths in RA; CV events occur a decade earlier than in population controls [1], suggesting that, as in diabetes
mellitus, RA is a significant independent risk factor for premature ischemic heart disease.
A number of publications have addressed the effects of RA-related risk factors on accelerated atherosclerosis, but
most  studies  were  cross-sectional,  finding  associations,  but  not  necessarily  causality  [2].  Another  limitation  of  the
published observational studies is the choice of carotid intima-media thickness (IMT) as a proxy for cardiovascular
diseases. In recent years the role of IMT as a marker of atherosclerosis has been questioned [3, 4]. Thickening of the
intima-media layer in common carotid arteries is usually caused by hypertrophy of the smooth muscle cells in the tunica
media in response to high shear stress, whereas the atherosclerotic process, particularly in its early phase, is restricted to
the intimal layer [5, 6]. Plaques usually occur at sites of low shear and nonlaminar turbulent flow such as in the carotid
bulb and the proximal internal carotid artery [6], and are rare in the distal part of common carotid arteries where IMT is
measured. Both autopsy studies and ultrasonographic studies have demonstrated that carotid plaque is more strongly
correlated with atherosclerosis  than IMT [7 -  10].  However,  the presence of plaque lacks reliability in detection of
atherosclerosis  progression,  because  longitudinally  plaque  growth  along  the  carotid  axis  of  flow  is  faster  than
thickening  toward  the  lumen  [11].
We hypothesize that  another imaging surrogate such as the sum of all  plaque areas in the carotid arteries (total
plaque area, TPA) may be more appropriate for the assessment of atherosclerosis progression in observational studies in
RA cohorts. TPA represents a carotid plaque burden and has been found to be a stronger predictor of coronary artery
disease than IMT [12, 13]. Measuring plaque on a continuous scale increases the ability to quantify the effect of and
interaction among risk factors compared with categorical classification (plaque presence). To the best of our knowledge,
data on predictive value of TPA in RA cohorts, as well as on progression of TPA and IMT in the same individuals have
not been published previously.
Since the morphological components of vessel damage, detected by ultrasound, may reflect different phenotypes of
atherosclerosis with distinctive relations to CV risk factors and to clinical vascular disease [5,  14],  we have used a
complex approach with the assessment of the total carotid plaque burden, pulse wave velocity and local wall elasticity,
and arterial hypertrophy by intima-media thickness, adjusting for confounders such as traditional and non-traditional
risk factors of CV disease in RA. The main objective was to determine risk factors for TPA at baseline as well as risk
factors  for  carotid  plaque progression (∆ TPA) in  a  small  well-characterized group of  active  RA patients  followed
serially.
MATERIAL AND METHODS
The study was conducted in full conformance with the principles of the “Declaration of Helsinki” and the protocol
was approved by the Health Sciences Research Ethics Committee of the Western University, Ontario, London, Canada.
All participants signed an informed consent form, after adequate explanation of the aims, methods, anticipated benefits,
and potential hazards of the study.
Study Design
This was an observational single-centre study to identify the CV risk factors (both traditional and non-traditional)
that may predict the presence of carotid plaque at baseline and progression over 24 weeks (which was chosen as that is
the length of usual RCTs of active RA patients) in order to estimate rates of progression in patients with active RA after
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adjusting to risk factors.
Patients
The study population was recruited over a period of 1 year and included 31 RA patients (out of 195 screened) with
evidence of active disease despite standard of care treatment. Inclusion criteria were age 18-80 years; RA > 3 months’
duration diagnosed according to ACR 1987 criteria; oral corticosteroids (≤10 mg/day prednisone or equivalent) and
NSAIDs (up to the maximum recommended dose) if the dose had been stable for at least 2 weeks prior to baseline;
moderate or high disease activity - the sum of the swollen joint count (SJC) (66 joint count) plus tender joint count
(TJC) (68 joint count) ≥8 at screening OR the sum of the SJC plus TJC ≥4 with elevated acute phase reactants (either
hs-CRP≥10 mg/l or ESR≥28 mm/h) at screening or within past 12 months.
To  avoid  confounding  by  other  inflammatory  conditions  and  treatments,  the  following  exclusion  criteria  were
employed:  major  surgery  within  8  weeks  prior  to  screening  with  residual  surgery  related  inflammation;  rheumatic
disease other than RA or uncontrolled significant systemic involvement secondary to RA (e.g. Felty’s syndrome), high
doses of steroids (>10 mg/day prednisone or equivalent, including parenteral and intra-articular administration within 4
weeks prior to baseline) and those initiating treatment with cell-depleting therapies within the past six months or/and
receiving lipid-lowering medications within 12 weeks of baseline. Participants were excluded if they were pregnant,
breastfeeding,  had  uncontrolled  comorbidities,  or  documented  ischemic  heart  disease  (previous  infarction,
revascularization  surgery,  angina,  or  heart  failure),  cerebrovascular  disease  (stroke  or  transient  ischemic  attack)  or
symptomatic peripheral artery disease.
Clinical Assessment
Clinical  information,  including  age,  sex,  and  disease  duration,  history  of  hypertension,  medications,  lifestyle
(smoking, alcohol, and exercise) was obtained. Height, body weight, waist circumference, and blood pressure were
measured. Participants were classified as overweight and obese if BMI was 25-29.9 kg/m2 and ≥30 Kg/m2, respectively.
An assessment of 66 joints for swelling and 68 joints for tenderness was made. The 4 variable disease activity score
(DAS28) was calculated using erythrocyte sedimentation rate and hsCRP [15, 16]. 100 mm horizontal visual analog
scales were used for global assessments of disease activity by the patient and physician, and pain. The Framingham risk
score for cardiovascular disease over 10 years was calculated [17]. Clinical characteristics were assessed on the same
day as the carotid ultrasound was performed.
Radiographic Assessment
A single  radiograph  of  the  hands  and  wrists  was  utilized  to  obtain  a  radiographic  damage  assessment  using  a
standardized tool: the Short Erosion Scale (SES) [18]. This scale uses a 6 joint, 12-item scale composed of wrist areas
1,2, and 4 and MCP joints 2,3 and 5 as defined in the Larsen method. A total maximum SES is 60 (12 joints with a
maximum score of 5 per joint).
Carotid Ultrasound Measurements
Carotid arteries of RA patients were scanned using a high resolution 3D ultrasound (REF Type of scanner) and the
following ultrasound parameters were recorded: presence or absence of plaque, total plaque area (TPA), carotid vessel
wall volume (VWV), and Intima-Medial Thickness (IMT). Detailed description of the ultrasound methods used in the
study is given in the Supplement 1. TPA was the sum of all plaques between the clavicle and the angle of the jaw in
both left and right carotid arteries. Significant plaque burden was determined by a measurement of total plaque area ≥
0.25 cm2.
DXA (Dual Energy Xray) Absorptiometry
Total  body  composition  parameters  were  assessed  by  DXA  using  a  Hologic,  Model  #QDR4500  (place)  with
standard software supplied by a software 12.3 version. Cockcroft-Gault equation: creatinine clearance was calculated as
(140-age) x weight in kg/(72xserum creatinine) in men, and (140-age) x weight in kg/(72 x serum creatinine X 0.85) in
women. The laboratory analyses were performed at the time of the carotid ultrasound and included standard hematology
and biochemistry  assessments,  fasting  lipid  profile  (total  cholesterol,  high-density  lipoproteins  (HDL),  low-density
lipoproteins (LDL), triglycerides), hsCRP, ESR, HbA1c, TSH, T4, FSH.
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Statistical Analysis
Values were  expressed as  the mean  (standard error; SE)  or percentages,  as appropriate.   Student’s  t-test or
 Mann Whitney U-test was applied for comparison between continuous variables, as well as chi-square or Fisher’s exact
test  for  categorical  variables.  Spearman’s  or  Pearson’s  tests  were  used  to  determine  the  correlation  between  TPA,
VWV, IMT, PWV, RA parameters and risk factors for atherosclerosis. A stepwise binary logistic regression analysis
was  performed to  determine  the  factors  influencing  the  presence  of  plaque.  Variables  entered  into  the  model  were
chosen if significantly associated in simple correlation analyses, and those variables known or previously associated
with atherosclerosis in RA, from published observations. To identify specific determinants of the plaque progression in
RA, linear regression analysis was used. The change in TPA was entered as the dependent variable, and demographic,
CVD risk factors and inflammatory variables were considered as independent variables. The results from the multiple
stepwise linear regression technique were presented as non-standardized regression coefficients (B) with standard error,
P-value and 95% confidence interval. All data were analyzed using SPSS 22.0 software, considering a two-tailed level
of P < 0.05 statistically significant.
RESULTS
One hundred ninety five patients with RA were screened, of whom one hundred sixty four were excluded for the
following reasons: 64 patients (39%) did not meet the inclusion criterion of disease activity, 39 (24%) received lipid-
lowering  drugs,  22  (13%)  had  either  malignancy  (7  patients)  or  uncontrolled  co-morbidities  (15  patients),  3  (2%)
underwent recent surgery, 4 (2%) had overlap with other rheumatic diseases, 12 (7%) were older than 80 years, 9 (5%)
met exclusion criteria of concurrent therapy (i.e. >10 mg/day prednisone), 11 (8%) were not compliant.
Table 1. Clinical and laboratory findings in patients with rheumatoid arthritis grouped according baseline atherosclerotic
plaque in carotid arteries.
Clinical characteristics RA patients with plaque, n = 11
RA patients without plaque, n =
20
P-value
Age, years (SE) 63.2 (8.9) 57.1 (9.8) 0.1
Disease duration, years 18.1 (12.0) 13.8 (9.5) 0.29
No. of pts with disease duration ≥10 years, n (%) 8 (73) 12 (60) 0.62
Physician’s global assessment of disease activity (0 to 100 mm) (SE) 29.1 (18.1) 20.9 (11.3) 0.34
Patient’s global assessment of disease activity (0 to 100 mm) (SE) 38.3 (32.3) 43.2 (24.1) 0.40
Pain (0 to 100 mm) (SE) 32.7 (27.6) 38.8 (21.1) 0.28
Short erosion score (SE) 21.4 (18.5) 14.6 (15.8) 0.34
Tender Joint Count (TJC) (0-68) (SE) 18.8 (10.5) 18.2 (13.6) 0.54
Tender Joint Count (0-28) (SE) 8.6 (5.0) 9.5 (6.9) 0.66
Swollen Joint Count (0-66) (SE) 9.2 (5.3) 10.0 (4.9) 0.73
Swollen Joint Count (0-28) (SE) 7.7 (4.3) 8.3 (4.1) 0.99
DAS 28-ESR (SE) 4.9 (1.1) 4.8 (1.3) 0.81
DAS 28-CRP (SE) 4.5 (1.2) 4.6 (1.2) 0.86
Hypertension, n (%) 7 (64) 10 (50) 0.46
Body mass index, kg/m2(SE) 27.6 (7.8) 30.6 (5.8) 0.36
Smoking history:
Current smokers, n (%)
Former smokers, n (%)
Never smokers, n (%)
9(36)
4 (36)
3 (28)
6(30)
7(35)
7 (35)
0.53
Average number of cigarettes/day in smokers (ever) 12.6 (7.9) 9.9 (7.6) 0.19
Number of smoking years (SE) 20.7 (20.2) 15.3 (14.6) 0.40
Pack-years 19.5 (16.9) 14.8 (10.4) 0.32
Family history of cardiovascular disease, n (%) 5 (46) 5 (25) 0.24
Framingham risk score 19.2 (12.1) 10.5 (6.6) 0.005
Creatinine clearance (Cockcroft-Gault equation) 0.93 (0.36) 1.16 (0.19) 0.002
Laboratory parameters
  ESR, mm/hr (SE) 30.2 (14.2) 17.7 (15.4) 0.009
  hsCRP, mg/l (SE) 9.5 (7.7) 6.7 (6.5) 0.33
  Total cholesterol, mmol/l (SE) 4.9 (0.8) 5.1 (0.8) 0.64
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Clinical characteristics RA patients with plaque, n = 11
RA patients without plaque, n =
20
P-value
  LDL cholesterol, mmol/l (SE) 2.9 (0.6) 3.0 (0.7) 0.42
  HDL cholesterol, mmol/l (SE) 1.52 (0.5) 1.4 (0.5) 0.52
  Total/HDL cholesterol (AI) (SE) 3.6 (1.5) 4.1 (1.5) 0.42
Values are expressed as means (SE) or percentages as appropriate. LDL: low-density lipoprotein; HDL: high-density lipoprotein; ESR - erythrocyte
sedimentation rate; AI - atherogenic index
Thirty  one  patients  met  inclusion  criteria  (27  female  and  4  male,  mean  age  59.3±9.8  years).  They  had  median
disease duration of fourteen years and a mean DAS28-ESR of 4.8 ± 1.2; where 43% had DAS28 ≥ 5.1. The median SES
was 21 (range from 0 to 60). Ninety-seven percent were receiving disease modifying anti-rheumatic drugs (DMARDs)
at  screening  visit,  alone  or  in  combination:  oral  hydroxychloroquine  (n=8),  weekly  oral  methotrexate  or  injectable
methotrexate  (n=  18),  leflunomide  (n=7),  sulfasalazine  (n=8),  D-penicillamine  (n=1),  and  TNFα inhibitors  (n=10).
Eleven patients were taking daily oral prednisone (n=11) at baseline.
Cardiovascular Risk Factors in Patients with RA
Traditional CV risk factors were frequent among the RA patients, including hypertension (55%), smoking (84%),
physical  inactivity  (61%),  obesity  (45%),  dyslipidemia  (68%),  diabetes  mellitus  (7%),  and  family  history  of
cardiovascular  disease  (32%).
At study entry, we identified 11 subjects with high atherosclerotic burden defined as a measurement of total plaque
area (TPA) ≥ 0.25 cm2 (Table 1). Those patients had a significantly greater Framingham risk scores (14.7±9.65 vs.
8.05±3.8,  p=0.005)  and  reduced  glomerular  filtration  rate  (0.93±0.36  vs.  1.16±0.19,  p=0.002),  an  independent  risk
factor for cardiovascular disease.
From the disease-related variables, ESR was significantly higher in RA patients with TPA ≥ 0.25 cm2 than in those
without plaque burden (30.18±14.21 vs. 17.68±15.37, p=0.009); all other parameters of disease activity and/or severity
were comparable in both groups. There was no difference in atherosclerotic burden for disease duration, DAS 28, and
SES.
Stepwise  binary  logistic  regression  analyses  showed  that  ESR  (OR=1.148,  95%CI:  1.015-1.299,  p=0.028)  and
Framingham  Risk  Factor  Score  (OR=1.155,  95%CI:  1.002-1.332,  p=0.046)  were  significant  predictors  of  plaque.
Traditional  risk factors (Framingham risk score) predicted the high atherosclerotic burden in 70%. 30% of patients
classified by Framingham risk score as low risk for CV events (<10%) had US-measures of significant atherosclerosis.
Modified  Framingham  risk  score  (1.5  multiplication  factor)  failed  to  identify  22%  of  the  patients  with  high
atherosclerotic  burden  (TPA≥0.25cm2)  and  20%  of  those  with  maxIMT≥0.8  mm.
The  groups  of  patients  with  and  without  high  atherosclerotic  burden  were  formed  on  the  basis  of  TPA
measurements, and TPA itself had a significant association with ESR (r=0.49, p=0.006) and Framingham risk score
(r=0.527, p=0.008).
Most patients (86%) had increased arterial thickness (maxIMT≥0.6mm) and half of them had maxIMT≥0.8mm.
Arterial stiffness and thickening was linked to smoking (pack-years was associated with PWV (r=0.64, p=0.008) and
IMT (r=0.48,  p=0.04)).  PWV showed a  positive  association with  age (r=0.53,  p=0.004).  Carotid  artery  vessel  wall
volume  did  not  show  any  statistically  significant  difference  between  the  groups  of  RA  patients  with  and  without
significant plaque burden (374.96±56.8mm3 vs. 334.16±71mm3, p=0.12) and it was not associated with RA-related
parameters and traditional CV risk factors.  Body mineral  density (BMD) of lumbar spine was slightly lower in the
group of RA patients with plaque (0.97±0.17 b/cm2 vs. 1.06±0.12 b/cm2, p=0.05), but all other parameters (BMD of
femur, total body mineral content, total fat,  total lean, total mass, percentage of fat) were similar in those with and
without high atherosclerotic burden.
Inflammation and Lipid Metabolism in Rheumatoid Arthritis
An atherogenic lipid profile characterized by reduced HDL levels and/or elevated atherogenic index (AI) occurred
in 68% of RA patients. The measures of disease activity (global assessments of disease activity by physician and by
patient, DAS-28, TJC 68, SJC 66) showed a strong positive association with dyslipidemia (Table 2).
(Table 1) contd.....
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Table  2.  Non-parametric  analysis  of  disease  activity  and  lipid  blood  levels  in  RA  patients  (Spearman’s  coefficient  of
correlation).
Lipid blood level DAS 28-hsCRP DAS 28-ESR Disease activity assessed
by physician
Disease activity
assessed by
patient
TJC68 SJC66
HDL, mmol/l R=-0.55, p=0.006 R=-0.67, p=0.0001 R=-0.11, p=0.59 R=-0.23, p=0.27 R=-0.422, p=0.036 R=-0.54, p=0.005
LDL, mmol/l R=0.24, p=0.3 R=0.39, p=0.06 R=0.39, p=0.049 0.46, p=0.02 R=0.4, p=0.047 R=0.26, p=0.2
AI R=0.627, p=0.001 R=0.79, p=0.0001 R=0.38, p=0.06 R=0.49, p=0.01 R=0.59, p=0.002 R=0.57, p=0.003
Total Cholesterol,
mmol/l
R=0.045, p=0.83 R=0.1,
p=0.6
R=0.42, p=0.028 R=0.35, p=0.08 R=0.25, p=0.2 R=0.12, p=0.55
LDL: low-density lipoprotein; HDL: high-density lipoprotein; AI –atherogenic index. *- p<0.05, **- p<0.005, ***- p<0.0005
The hsCRP blood levels were related to disease activity as measured by Physician’s global assessment (r=0.443,
p=0.016), and traditional CV risk factors: LDL (r=0.544, p=0.007), family history of CV events (r=0.464, p=0.011), and
smoking (pack-years) (r=0.384, p=0.4, n=29).
Table 3. Univariate linear regression analysis of independent variables (predictors) of atherosclerotic plaque progression in
RA patients.
Predictor Unstandardized Coefficients Standardized Coefficients t Sig. 95.0% Confidence Interval for B
B Std. Error beta Lower Bound Upper Bound
hsCRP, mg/l .020 .005 .844 4.451 .002 .010 .030
ESR, mm/h .013 .004 .789 3.401 .011 .004 .021
Daily N. of cig. .025 .007 .838 3.434 .019 .006 .043
Pack-years .011 .003 .892 4.411 .007 .005 .018
Predictors of Plaque Progression
Ten patients from the primary cohort who had baseline significant plaque burden were recruited into a 24 Week
prospective study. The medications taken for RA during the 24-week period remained stable. One patient was lost to
follow-up. All of the assessments described above were conducted at baseline, and repeated at 24 weeks. There were no
changes  found  between  baseline  and  FU  IMT measurements  (0.763±0.134mm and  0.769±0.133mm,  respectively).
Mean (±SD) TPA at baseline was 0.43±0.18cm2 and 0.52±0.29cm2- at FU visit. Fig. (1) shows the plaque progression in
Fig. (1). Baseline and 24-week 3D ultrasound measures of total plaque area (TPA) in patient with rheumatoid arthritis indicative of
atherosclerotic plaque progression (TPA baseline - 0.44mm2 and TPA at week 24 - 0.68mm2). The cross-sectional area of each
plaque was measured in the longitudinal view. TPA was the sum of all plaques between the clavicle and the angle of the jaw in both
left and right carotid arteries.
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RA patient. ∆TPA did not always parallel ∆IMT: three patients with an increase in TPA measurements (∆TPA 0.1, 0.24
and  0.45cm2)  did  not  show  any  IMT  changes.  Linear  regression  analysis  was  performed  to  determine  predictors
(independent  variable)  of  the  plaque  progression  assessed  by  the  pairwise  comparison  of  baseline  TPA  and  the
subsequent measurement time (dependent variable) (Table 3). The ESR and hsCRP were observed to have a significant
effect on the increase in plaque size (β=0.79, p=0.01 and β=0.85, p=0.002, respectively), as well as smoking (number of
pack-years: β=0.89, p=0.007, and daily number of cigarettes: β=0.84, p=0.02) by univariate linear analysis. Because of
the limited number of RA patients who had baseline plaque, we evaluated the relationship between the predictor and
outcome controlling for other predictors by introducing into the models (stepwise method) hsCRP together with (one at
a time) traditional risk factors and RA-related parameters. Stepwise linear regression analysis revealed that only hsCRP
was a significant risk factor for TPA progression in RA patients (B=0.019, SE=0.003, β=0.947, p=0.004). Smoking and
ESR were  cofounders  associated  with  hsCRP.  We did  not  find  any  associations  between  disease  characteristics  or
traditional CV risk factors and ∆IMT by linear regression analysis.
DISCUSSION
We observed a high prevalence of 3DUS measurements of significant atherosclerotic burden (35%) and arterial wall
hypertrophy (86%) in RA patients with long disease duration and active RA at baseline. These findings were greater
than would be expected in age and sex matched controls [19]. Similar to our findings, Roman et al. (2006) reported that
plaque was three times more prevalent in the patients with RA than in controls in all decades of life [20]. Another cross-
sectional study also revealed an increased prevalence of severe subclinical atherosclerosis in long standing RA: 72% of
RA patients had atherosclerosis and 31% had plaque in that cohort [21].
Traditional risk factors such as hypertension, type 2 diabetes, smoking, hypercholesterolemia, obesity and physical
inactivity explain at least some of the excess CV risk in RA patients [22, 23]. We observed that the Framingham risk
score  as  a  composite  measure  of  the  burden  of  traditional  risk  factors  predicted  atherosclerotic  plaque  in  RA,  and
smoking  was  associated  in  univariate  analysis  with  worsening  atherosclerotic  plaque  at  24  weeks.  In  recent  meta-
analysis,  Baghdadi  et  al.  showed that  CV events  in  RA patients  were  strongly  associated  with  hyperlipidemia  and
hypertension,  while  RA duration  and  erosions  were  less  significant  contributors  [23].  However,  the  application  of
traditional CV risk factor assessment equations, such as Framingham, Reynolds risk score and the Systematic Coronary
Risk Evaluation models, to patients with RA is reported to underestimate their CV risk [24]. Accordingly, we found that
Framingham risk score predicted the high atherosclerotic burden only in 70% of patients.
Systemic inflammation significantly contributes to the rapid progression of subclinical atherosclerosis in RA [25].
We found that hsCRP and ESR were strongly associated with atherosclerotic plaque growth over 24 weeks. Moreover,
ESR was the  best  predictor  of  atherosclerotic  burden in  our  primary RA cohort.  Similar  to  our  results,  some other
studies have demonstrated a significant association between ESR and the risk of CVD [26, 27]. The CRP at baseline has
been found to be an important predictor of subsequent death from CV disease in patients with new onset inflammatory
polyarthritis  and  was  independent  of  other  factors  of  disease  severity  [28].  The  magnitude  and  chronicity  of  the
inflammatory  response,  as  measured  by  CRP,  correlated  with  carotid  atherosclerosis  development  in  RA [29].  We
found  that  hsCRP levels  were  significantly  linked  to  LDL in  RA.  It  is  also  possible  that  under  high  inflammatory
burden,  excessive  production  of  acute  phase  reactants  may  impair  trafficking  of  cholesterol  in  the  liver  or  impede
normal cholesterol production. RA-related inflammation not only influences the plaque progression, but also promotes
plaque vulnerability. Higher plaque vulnerability has been reported in patients with active RA, potentially contributing
to future CV events [30]. These findings point to the critical importance of adequate disease control in lowering CV
risk. The modified CV risk evaluation model, which would incorporate the impact of systemic inflammation, has yet to
be developed. The use of 1.5 multiplication factor recommended for RA patients [31] did not improve risk estimation in
our RA cohort: modified Framingham risk score failed to identify a quarter of patients with significant atherosclerotic
burden detectable by 3DUS.
Most  patients  with  active  RA had  an  atherogenic  lipid  profile:  low  HDL and  thus  an  increased  TC/HDL ratio
(atherogenic index), which is an important prognostic marker for CVD [32]. The available literature on lipid profiles in
patients  with  RA is  contradictory  [33,  34].  A  higher  disease  activity  measured  by  DAS 28  and  Physician’s  global
assessment in our study was associated with higher LDL levels, lower total cholesterol and HDL levels, leading to an
unfavorable  atherogenic  index.  Similar  to  our  study,  the  serum  total  cholesterol  and  HDL  levels  in  RA  were
demonstrated to  be  inversely  linked to  disease  activity:  patients  in  remission or  with  controlled disease  showed an
increase in HDL levels and a reduction in the atherogenic index compared to patients with active disease [35]. These
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findings have been recently confirmed by a larger cross-sectional study in 204 patients with RA, demonstrating an
adverse  effect  of  disease  activity  on  lipid  profile  [36].  However,  the  temporal  and  casual  relationships  between
inflammation and changes in lipids are still unclear. RA-related inflammatory milieu might adversely affect the lipid
profile  directly  via.  cytokine  production  (TNF-α,  IL-6),  as  well  indirectly  leading  to  the  modifications  of  lifestyle
factors (i.e impaired physical activity) and sharing a common genetic predisposition to RA and dyslipidemia [37 - 39].
We must acknowledge a number of study limitations. First, this was a small pilot study, involving only subjects who
met the strict inclusion and exclusion criteria and consented to US monitoring. Only active RA patients were included
which limits the generalizability of findings (most RA patients who were screened were not eligible). This could also
affect power to detect the link between disease activity measures and atherosclerosis in a cross-sectional portion of the
study, because disease activity range was small across the recruited subjects. In chronic inflammatory diseases such as
RA, the individual inflammatory markers’ concentrations (i.e. hsCRP) frequently fluctuate during the course of disease
making  the  impact  of  such  changes  on  CV  risk  less  clear.  To  overcome  this  limitation,  we  used  some  surrogate
measures of disease progression, such as the ratio of joint damage over disease duration, and the number of DMARDs
used in the past, as an attempt to quantify the total inflammatory burden of disease. The burden of inflammation seems
to  be  more  important  than  isolated  measurement  of  inflammatory  markers,  such  as  CRP,  for  progression  of
atherosclerosis and cardiovascular mobility and mortality. Further longitudinal studies with follow-up assessments of
radiographic damage scores over observation period are warranted to estimate a total effect of the chronic inflammation
on atherosclerosis progression.
The effect of RA treatment on atherosclerosis is important to consider. The proportion of patients in our study was
receiving non-biologic DMARD therapies, and/or TNF-inhibition therapy. TNF-α inhibitors and methotrexate may be
cardioprotective in RA [40] and thus influence the study results. For tracking atherosclerotic lesion changes over time,
we used  a  3DU carotid  ultrasound measurement  of  TPA.  Our  approach  to  the  evaluation  of  the  carotid  ultrasound
parameters  was  based  on  a  recent  randomized  placebo  controlled  study  [41],  where  the  treatment  with  high  dose
atorvastatin resulted in a statistically significant and clinically relevant decrease in TPA. These measurements have also
been utilized in a diabetic patient population providing greater dynamic range and allowing for statistically significant
differences in plaque progression as compared to IMT progression [42 - 44]. IMT is a small structure, and changes over
time representing only tenths of millimeter, that is, the resolution of the B-mode image is below the quantities being
measured. Indeed, we did not find any reliable associations of IMT changes over time with CV risk factors in our group
of patients. The fact that plaques are larger structures makes TPA more suitable for longitudinal measurements at an
individual level.
CONCLUSION
In  conclusion,  a  high  prevalence  of  carotid  artery  atherosclerosis  was  detected  in  active  RA with  long  disease
duration. Along with the increased burden of traditional cardiovascular risk factors, RA-related systemic inflammation
significantly contributed to the occurrence and progression of atheroma and might mediate its effects on atherosclerosis
through hsCRP and modulation of traditional risk factors, such as dyslipidemia. Thus, achieving disease remission is
crucially important in lowering CV risk in RA patients; a new CV risk estimation model or adjustment method in RA
patients is required.
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